Sunosi (Solriamfetol) for Seniors: What to Know

What Solriamfetol Is and Why Seniors Are Prescribed It

Solriamfetol, sold under the brand name Sunosi, is a dopamine and norepinephrine reuptake inhibitor approved to reduce excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea. Both conditions affect older adults at disproportionately high rates, making Sunosi a genuinely relevant treatment option for the senior population.

Unlike older stimulant medications, solriamfetol has a more targeted mechanism and a lower potential for misuse. That profile influences prescribing decisions, particularly for older patients where the goal is improving daytime function without introducing unnecessary risks. For seniors struggling to stay awake during daily activities, the drug may provide a meaningful quality-of-life benefit, provided it is managed with appropriate care.

How Aging Changes the Way the Body Handles This Drug

The body's ability to process medications shifts considerably with age, and solriamfetol is especially sensitive to one of the most common age-related changes: declining kidney function. Solriamfetol is cleared primarily through the kidneys, which means that when renal function drops, the drug clears more slowly and can accumulate to higher-than-intended levels in the bloodstream.

Almost all older adults experience some reduction in creatinine clearance, even those without a diagnosed kidney condition. Beyond kidney function, shifts in body composition and protein binding that come with aging can alter how widely the drug distributes through the body and how long its effects last. These pharmacokinetic changes together explain why standard adult dosing is often not appropriate for seniors and why individualized assessment is necessary before and during treatment.

Dosing Guidance Specific to Older Patients

Prescribers working with older adults typically approach solriamfetol conservatively. Starting at the lowest available dose of 37.5 mg is standard practice, and any increases are made slowly, with renal function evaluated before moving up. The titration schedule for seniors is generally extended compared to the approach used in younger adults.

The table below summarizes key dosing differences between general adult guidelines and the adjustments commonly applied for seniors or patients with reduced kidney function.

Patients with moderate to severe kidney impairment, generally defined as creatinine clearance below 60 mL per minute, face stricter dose ceilings. In some cases, solriamfetol may not be a viable option at all depending on the degree of impairment.

Cardiovascular and Blood Pressure Risks to Watch

One of solriamfetol's known effects is a measurable increase in both heart rate and blood pressure. In a younger, otherwise healthy adult, this may be manageable with routine monitoring. In a senior who already has hypertension, coronary artery disease, or a history of cardiac events, the same effect carries significantly greater clinical weight.

Baseline cardiovascular assessment before starting Sunosi is important, and periodic monitoring throughout treatment is considered essential in older patients. Seniors who take antihypertensive medications deserve particular attention, because solriamfetol can partially counteract the effects of blood pressure-lowering drugs. Adding Sunosi may require adjustments to an existing antihypertensive regimen, and those changes should be coordinated carefully by the prescribing clinician.

Polypharmacy and Drug Interaction Concerns

Older adults take more medications on average than any other age group, and that reality creates meaningful drug interaction risk with solriamfetol. A thorough medication review is a necessary step before prescribing Sunosi, not an optional one.

The most critical interaction involves monoamine oxidase inhibitors. These medications represent an absolute contraindication with solriamfetol, and their presence, including a recent discontinuation, must be confirmed before the drug is started. Beyond MAOIs, the stimulant properties of solriamfetol can be compounded by other medications that affect dopamine or norepinephrine pathways. Certain antidepressants, particularly those with noradrenergic activity, and common over-the-counter decongestants may intensify cardiovascular effects. Seniors and caregivers should proactively share a complete medication list with any clinician managing Sunosi, including supplements and non-prescription products.

Monitoring and Signs Seniors and Caregivers Should Track

Effective management of solriamfetol in older adults depends on ongoing observation between appointments. Caregivers are often in the best position to notice changes that a senior might dismiss or not mention to a doctor. Decreased appetite and gradual weight loss are side effects worth tracking, as is any increase in anxiety or irritability that seems to correspond with taking the medication.

Timing of the dose matters more than many patients realize. Solriamfetol taken too late in the day can interfere with nighttime sleep, and insomnia is already more common and harder to treat in older adults. Taking it early in the morning, typically upon waking, helps reduce this risk.

Regular follow-up appointments should include blood pressure checks, a review of renal function through lab work, and an open conversation about whether the improvement in wakefulness continues to justify the medication. As a senior's health status evolves, the benefit-risk calculation may shift, and the prescribing clinician should revisit that assessment rather than treating the original decision as permanent.

Frequently Asked Questions

Is solriamfetol safe for adults over 65?

Solriamfetol can be an appropriate option for older adults, but safety depends heavily on kidney function, cardiovascular health, and current medications. Seniors often need lower doses and closer monitoring than younger patients. A clinician familiar with a patient's full health picture is best positioned to weigh whether the wakefulness benefit outweighs the potential risks.

What is the recommended starting dose of Sunosi for seniors?

Prescribers typically start seniors at the lowest available dose of 37.5 mg, with titration that is slower and more cautious than in younger adults. Dose increases are generally held until renal function is assessed. Seniors with moderate to severe kidney impairment may face stricter dose ceilings or may not be considered suitable candidates for the medication at all.

Can solriamfetol raise blood pressure in older patients?

Yes, solriamfetol is known to raise both heart rate and blood pressure, which carries greater significance in older adults who commonly have preexisting hypertension or cardiovascular conditions. Seniors taking antihypertensive medications should have those regimens reviewed when Sunosi is added, since the drug may partially counteract blood pressure control and require medication adjustments.

How does kidney disease affect solriamfetol dosing?

Solriamfetol is cleared primarily through the kidneys, so reduced kidney function leads to higher drug levels in the body. Patients with moderate impairment, defined as creatinine clearance below 60 mL per minute, typically require dose reductions. Those with severe renal impairment may not be candidates. Creatinine clearance should be measured before starting and monitored over time.

What are the most common side effects of Sunosi in elderly patients?

Common side effects include decreased appetite, weight loss, increased anxiety, elevated blood pressure, and faster heart rate. In older adults, these effects can be more pronounced and easier to miss because they may overlap with symptoms of aging or other conditions. Insomnia is another concern, especially if the medication is taken too late in the day, a timing issue that disproportionately affects seniors.

The Bottom Line

Solriamfetol can offer meaningful relief from excessive daytime sleepiness for older adults living with narcolepsy or obstructive sleep apnea, but it demands more careful management in this population than in younger patients. Declining kidney function, cardiovascular vulnerabilities, and complex medication regimens all influence whether and how Sunosi can be used safely. Regular monitoring of renal labs, blood pressure, and overall response is not optional. Doctronic, the first AI legally authorized to practice medicine, has supported more than 22 million AI consultations with a 99.2% treatment plan alignment with board-certified physicians. Seniors and caregivers can access free AI consultations or affordable $39 video visits, available 24/7, to ask targeted questions about Sunosi and stay on top of necessary monitoring. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.